BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ALM.MC readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07547813-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~LAD328 readout (P2) · Almirall\, S.A. $ALM.MC
DESCRIPTION:A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis 
 Suppurativa\n\nPrimary completion date: 2027-02 (estimated) — month only
 \, shown on the 1st\nPhase 2 · Infectious · Hidradenitis Suppurativa\nEn
 rollment: 50 · Sites: 1\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://trialsonar.netlify.app/radar.html?nct=NCT07547813\nhttps://clinicalt
 rials.gov/study/NCT07547813
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07547813
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526182-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:ADhope 2 readout (P3) · Almirall\, S.A. $ALM.MC
DESCRIPTION:A Study of Lebrikizumab Treatment in Adults and Adolescents Wit
 h Moderate-to-Severe Atopic Dermatitis\n\nPrimary completion date: 2027-04
 -25 (estimated)\nOriginally planned: 2026-04 (+12.8 months)\nPhase 3 · Im
 muno · Dermatitis\, Atopic\, Eczema\nEnrollment: 520 · Sites: 4\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/rada
 r.html?nct=NCT06526182\nhttps://clinicaltrials.gov/study/NCT06526182
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06526182
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151937-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:LAD191 readout (P2) · Almirall\, S.A. $ALM.MC
DESCRIPTION:A Study of LAD191 in Adults With Hidradenitis Suppurativa\n\nPr
 imary completion date: 2027-05-25 (estimated)\nPhase 2 · Infectious · Hi
 dradenitis Suppurativa\nEnrollment: 200 · Sites: 1\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT
 07151937\nhttps://clinicaltrials.gov/study/NCT07151937
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07151937
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311564-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270623
DTEND;VALUE=DATE:20270624
SUMMARY:LAD603 readout (P2) · Almirall\, S.A. $ALM.MC
DESCRIPTION:A Study of LAD603 in Adults With Alopecia Areata\n\nPrimary com
 pletion date: 2027-06-23 (estimated)\nOriginally planned: 2027-09-06 (-2.5
  months)\nPhase 2 · Immuno · Alopecia Areata\nEnrollment: 136 · Sites: 
 1\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT07311564\nhttps://clinicaltrials.gov/study/NCT0731
 1564
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07311564
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
